BioCryst Reports Q1 Loss Driven by Non-Cash Charge, Maintains Guidance, and Secures Navenibart Licensing Deal
BCRX sits 50% above its 52-week low of $6.
Summary
BioCryst Pharmaceuticals reported a large Q1 GAAP loss due to a non-cash acquisition charge, but showed strong ORLADEYO revenue growth, maintained its full-year guidance, and announced a significant European licensing deal for navenibart.
Key Events · Earnings and Guidance · BCRX
-
Q1 2026 Financial Results
Reported a GAAP operating loss of $701.6 million and a net loss of $721.8 million ($2.98 per share), primarily driven by a $697.8 million non-cash expense for acquired in-process R&D from the Astria Therapeutics acquisition. Non-GAAP operating profit was $54.2 million.
-
Strong ORLADEYO Revenue Growth
Q1 2026 ORLADEYO net revenue reached $148.3 million, an 11% increase year-over-year (21% on a comparable basis excluding European revenue).
-
European Licensing Agreement for Navenibart
Secured a licensing agreement with Neopharmed Gentili for exclusive European commercial rights to navenibart, including $70 million upfront, up to $275 million in future milestones, and tiered royalties (18-30%). This follows the initial announcement on May 4, 2026.
-
Maintained 2026 Financial Outlook
Reaffirmed full-year 2026 global net ORLADEYO revenue guidance of $625 million to $645 million and total revenue of $635 million to $660 million, along with non-GAAP operating expense guidance.
Analysis · BCRX · Life Sciences
BioCryst Pharmaceuticals reported a significant GAAP operating loss of $701.6 million and a net loss of $721.8 million for Q1 2026, primarily due to a substantial non-cash expense of $697.8 million related to acquired in-process research and development from the Astria Therapeutics acquisition. Despite this accounting charge, the company achieved a non-GAAP operating profit of $54.2 million, demonstrating underlying operational strength. ORLADEYO, the company's key product, continued strong revenue growth, and the full-year 2026 financial outlook was maintained, which is a positive signal of confidence. Additionally, the company secured a European licensing agreement for navenibart, bringing in $70 million upfront and potential future milestones, further strengthening its financial position and validating its pipeline. This comprehensive update provides a mixed financial picture but highlights strategic progress and a stable outlook.
At the time of this filing, BCRX was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $6.00 to $11.31. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.